---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-26-000011"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:23:00.625793+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q1 revenue $273M, raises FY product revenue guidance to $750-850M

## Summary
- Q1 2026 total revenue $273M; product revenue $226M, up 47% YoY.
- Net loss $2.8M vs net income $866.6M in Q1 2025 (prior year included non-recurring gain).
- Sephience revenue $124.6M, up 36% QoQ; 1,244 patients on commercial therapy globally.
- FY 2026 product revenue guidance raised to $750-850M; total revenue expected $1.08-1.18B.
- Positive votoplam PIVOT-HD data; $50M milestone from Novartis triggered in Q2 2026.

## SEC filing metadata
- accession: 0001070081-26-000011
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000011/0001070081-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000011/tmb-20260507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-26-000011
- JSON: https://secwatch.observer/filing/0001070081-26-000011.json
- Plain text: https://secwatch.observer/filing/0001070081-26-000011.txt

## Source-grounded claims
- claim_id: 4a668d9f30ff235caa3b205ce07fb87ac3ffed6b
  claim: PTC THERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: revenue $273 million, net income Net loss was $2.8 million for the first quarter of 2026. Guidance raised.
  evidence_excerpt: PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results – First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000011/0001070081-26-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.